Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.53

€1.53

8.130%
0.115
8.130%
-
 
15:19 / Tradegate WKN: A41QA9 / Name: Lir Life Sciences Corp. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Lir Life Sciences Corp. Stock

A very strong showing by Lir Life Sciences Corp. today, with an increase of €0.12 (8.130%) compared to yesterday's price.

Pros and Cons of Lir Life Sciences Corp. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform

Vancouver, Canada – January 8, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered

LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor

Vancouver, Canada – December 18, 2025 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that Dr. Peter Singer, a global

LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies

Vancouver, Canada – December 11, 2025 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent